Empagliflozin 10 mg Tablet
Empagliflozin 10mg
Tablet · Prescription medication
Samsung Pharmaceutical Co., Ltd.
MFDS item code 202102074 · Approved 2021.03.05
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication helps control blood sugar levels in adults with type 2 diabetes. It can be used alone or in combination with other diabetes medications along with dietary and exercise therapies. If blood sugar control is difficult with monotherapy, it may be used in combination with several agents including metformin. Additionally, it is used in combination if sufficient control is not achieved with insulin therapy or other combination therapies. This medication assists in effectively managing the condition of type 2 diabetes patients by improving blood sugar control.
The recommended dose of this medicine is 10 mg once daily for monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations •Patients with renal impairment No dose adjustment is required for patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent glomerular filtration rate < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. •Patients with hepatic impairment No dose adjustment is required for patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. •Elderly patients No dose adjustment is required based on age. Renal function and the risk of volume depletion should be considered in patients 75 years of age and older. Initiation of this medicine is not recommended in patients 85 years of age and older because clinical experience is limited (see Precautions for Use, 4. General Precautions).
This medication should not be used in patients with allergies to the active ingredient or any components of this drug. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis, nor to patients with severely impaired kidney function, end-stage renal disease, or those on dialysis. This medication contains lactose, thus it should not be given to patients with lactose intolerance, galactose intolerance, or certain genetic lactase deficiency. For patients with compromised kidney function, this drug should be used cautiously, with regular monitoring of kidney function to determine dose adjustment or discontinuation. In patients with mild to moderate heart failure, caution should be exercised, and it is not recommended for patients with severe heart failure. When used in conjunction with insulin or medications that stimulate insulin secretion, there is a risk of hypoglycemia, so insulin doses may need to be reduced. This medication may cause side effects such as hypoglycemia, genital infections, urinary tract infections, increased urination, decreased fluid volume, elevated serum creatinine, etc. If any unusual symptoms occur, immediate consultation with a healthcare professional is advised. Particularly, diabetic ketoacidosis, a serious metabolic acidosis, may rarely occur. If symptoms like nausea, vomiting, abdominal pain, or difficulty breathing appear, immediate medical attention is required. Elderly patients, especially those over 75 years, are at higher risk of fluid loss and should be monitored closely; temporary discontinuation may be necessary in situations where fluid loss is possible. This medication may affect urination, so patients with bladder-related diseases should consult their doctor. It is recommended that women who are pregnant or planning to become pregnant do not use this medication and breastfeeding women should cease breastfeeding while taking this medication. The safety and efficacy of this medication in pediatric patients under 18 years have not been established, hence it is not used in this age group. No specific toxic symptoms have been reported in cases of overdose; however, appropriate treatment is necessary based on clinical status. Keep this medication out of reach of children, and transferring it to another container may not maintain its quality properly. This medication may interact with other drugs, so inform your healthcare provider of any other medications you are taking. There is a risk of hypoglycemia when driving or operating machinery, so caution is advised. Cases of serious side effects, such as limb amputations, have been reported; hence, diabetic patients should pay close attention to foot care. If symptoms such as pain, swelling, or redness around the genital area occur while taking this medication, immediate confirmation and treatment for perineal necrosis should be sought.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to prevent air and moisture from entering, and keep it at room temperature between 1 and 30 degrees Celsius. Storing it this way can help maintain the drug's effectiveness for a longer duration.
Light yellow, round film-coated tablet with a convex surface on both sides
10 tablets/box [(10 tablets/PTP×1)], 30 tablets/box [(10 tablets/PTP×3)], 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 10mg
Tablet · Prescription medication
Samsung Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.